 |
David V. Goeddel, Ph.D.
|
Executive Chairman
|
| John K. Celebi, MBA |
Chief Business Officer |
| Guoqing Chen, Ph.D. |
VP of Research |
| Paul W. Sauer, MBA |
VP of Process Development |
 |
David V. Goeddel, Ph.D.
|
Executive Chairman |
| John D. Diekman, Ph.D. |
| Carl L. Gordon, Ph.D., CFA |
| Robert Schreiber, Ph.D. |
 |
Robert Schreiber, Ph.D.
|
Chairman |
| Rudolf Aebersold, Ph.D. |
|
| Frederick Appelbaum, M.D. |
|
| Thomas Kipps, M.D., Ph.D. |
|
| Richard Klausner, M.D. |
|
| Jeffrey V. Ravetch, M.D., Ph.D. |
|
| Richard Ulevitch, Ph.D. |
|
| Emil Unanue, M.D. |
|
| |
| |
| |
|
|
 |
Dr. Gordon is a founding General Partner of OrbiMed and Co-Head of Private Equity. Dr. Gordon is active in both private equity and small-capitalization public equity investments. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. Dr. Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a Bachelors degree from Harvard College. |
|